Mirxes Joins Prestigious Hang Seng Composite Index, Bolstering Market Position and Access to Key Investors
Mirxes, a leading and only public-listed molecular cancer early detection company in Asia Pacific, today announced its inclusion in the Hang Seng Composite Index (HSCI), effective 8 September 2025. This significant milestone elevates the company’s market profile and enhances its strategic position within the Hong Kong and wider Asian capital markets.

Learn MoreFormer Japanese PM Yukio Hatoyama Launches Nationwide Gastric Health Initiative with Mirxes' GASTROClear™
Former Prime Minister Yukio Hatoyama launched a nationwide public health initiative focused on gastric health and early detection of gastric cancer in Japan, leveraging GASTROClear™. Co-initiated by Mr. Hatoyama, Mirxes Japan and Nagawa Pharmaceutical, the ambitious initiative will offer free screening to 10,000 residents across Japan.

Learn MoreMirxes Soars as Southeast Asia’s First Biotech Unicorn, Following Blistering HKEX Debut
Mirxes Holding Company Limited (the “Company”; Stock code: 2629) marked a significant milestone today as its shares debuted on the Main Board of The Stock Exchange of Hong Kong Limited (HKEX), closing its first day of trade as a new biotech unicorn with a market capitalisation of HK$8.29 billion (US$1.06 billon).

Learn MoreMirxes Announces US$40M Synthetic Royalty-Backed Financing from CBC Group’s R-Bridge to Accelerate Global Growth
Mirxes, a leading RNA technology company specializing in early cancer detection and precision medicine, today announced a US$40 million structured financing transaction with CBC Group’s R-Bridge Healthcare Fund (“R-Bridge”). This partnership will provide critical support for Mirxes’ ambitious growth and expansion into key global markets.

Learn MoreMirxes and PULSE TCM launches holistic “East Meets West” community health screening pilot
In a First-In-Singapore collaboration, leading RNA technology company Mirxes and PULSE TCM, a renowned provider of traditional Chinese Medicine (TCM) services, today launched the holistic “East Meets West” Community Health Screening Pilot at Bukit Gombak. Witnessed by Ms Low Yen Ling, Senior Minister of State, Ministry of Culture, Community and Youth, Ministry of Trade and Industry, Mayor of South West District and Grassroots Adviser to Bukit Gombak Grassroots Organisations, this pilot represents a novel approach towards integrating contemporary Western precision diagnostic technology with Eastern TCM wisdom, aimed at creating an integrated approach to preventive and personalised healthcare for a Healthier Singapore.

Learn MoreOfficial opening of Singapore’s pioneering public-private partnership centre for specialty molecular testing
The National University Hospital (NUH) and Mirxes are proud to announce the official opening of the NUH DMOC@Biopolis, one of Singapore’s first publicprivate partnership centres for specialty molecular testing. The NUH DMOC@Biopolis is an extension of NUH’s Diagnostic Molecular Oncology Centre (DMOC) that co-locates and integrates with Mirxes’ clinical laboratory, M Diagnostics at Biopolis. The Centre was inaugurated today by Deputy Prime Minister, Coordinating Minister for Economic Policies, and Chairman of the National Research Foundation (NRF), Mr Heng Swee Keat.

Learn MoreMirxes receives FDA’s Breakthrough Device Designation for GASTROClearTM to advance blood-based cancer early detection
Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases accessible on a global scale, announced today that its flagship product GASTROClearTM, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S.

Learn MoreSlide Slide Slide Slide Slide Slide Slide

Our Science & Pipeline

At MiRXES, we harness the power of RNA to deliver early, actionable and personalized diagnoses across the care continuum to improve and save lives. Prevention is better than cure.

With early detection, mitigating risk factors and implementing prevention strategies, most cancer deaths can be prevented.

Our science opens us to a world without late-stage cancer diagnoses. This is how we improve and save lives.

Learn about Our Technology

MiRXES endeavors to be at the forefront of disease early detection and interception.

Learn about Our Pipeline

Delivering Our Solutions

One in four people has cancer in the world today. At MiRXES, we know the importance of science in the fight against cancer.

We understand that to make the most impact in improving and saving lives, we must translate and deliver our innovative solutions from the lab to clinic.

Read more about how our solutions that range from industry-leading discovery tools and services to diagnostic tests for cancer, cardiovascular, metabolic and infectious diseases, and precision oncology can enable you to act sooner – when it matters most.

Learn about Our Solutions

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.

Cookie Settings Accept All

Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the ...

Necessary

[x] Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
| Cookie | Duration | Description |
| --- | --- | --- |
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |

Functional

[x] Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Performance

[x] Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Analytics

[x] Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

[x] Advertisement

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Others

[x] Others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

SAVE & ACCEPT

Scroll to Top

MiRXES Pte Ltd

Extra Info

Homepage

A NEW DAWN

in disease early interception

Featured

Our Science & Pipeline

Delivering Our Solutions

SOCIAL MEDIA

ABOUT

SOLUTIONS

TECHNOLOGY

PIPELINE

NEWSROOM

Copyright © 2025 MiRXES Pte Ltd. All rights reserved. | Privacy Policy

Privacy Overview

Similar Businesses

GenScript Biotech (Singapore) Pte. Ltd.

Moleac Pte Ltd

BioAcumen Global Pte Ltd

ACM Biolabs

i-DNA Biotechnology Pte Ltd

Nuevocor Pte. Ltd.

Hummingbird Bioscience

Biosyngen Pte Ltd

Axil Scientific Pte Ltd

Biocon Solutions Pte Ltd

Austrianova Singapore Pte. Ltd.

Probioscience Technologies

Biofourmis

Atlantis Bioscience Pte Ltd

Amgen Singapore Manufacturing

Takeda Manufacturing Singapore Pte Ltd - Main Building

Featured In

Singapore Biomedical Learning & Development